ASTRAZENECA PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10,946 GBX | +0.29% |
|
-0.15% | +3.26% |
| Apr. 17 | AstraZeneca: presents new data at ECCMID | CF |
| Apr. 17 | The market is pinning its hopes on earnings reports |  |
Financials (USD)
| Sales 2024 * | 50.77B | Sales 2025 * | 54.26B | Capitalization | 211B |
|---|---|---|---|---|---|
| Net income 2024 * | 8.74B | Net income 2025 * | 10.24B | EV / Sales 2024 * | 4.54 x |
| Net Debt 2024 * | 19.66B | Net Debt 2025 * | 12.86B | EV / Sales 2025 * | 4.12 x |
| P/E ratio 2024 * |
24.6
x | P/E ratio 2025 * |
20.9
x | Employees | 89,900 |
| Yield 2024 * |
2.28% | Yield 2025 * |
2.4% | Free-Float | 96.44% |
More Fundamentals
* Assessed data
More news
Latest transcript on AstraZeneca PLC
More recommendations
More press releases
More news
| 1 day | +0.29% | ||
| 1 week | -0.15% | ||
| Current month | +2.51% | ||
| 1 month | +6.38% | ||
| 3 months | +4.93% | ||
| 6 months | +3.15% | ||
| Current year | +3.26% |
1 week
10 764.00
11 080.00
1 month
10 154.0011 184.02
Current year
9 461.0011 184.02
1 year
9 461.0012 348.00
3 years
7 360.0012 392.00
5 years
5 626.0012 392.00
10 years
3 680.0012 392.00
| Managers | Title | Age | Since |
|---|---|---|---|
Pascal Soriot
CEO | Chief Executive Officer | 63 | 12-09-30 |
Aradhana Sarin
DFI | Director of Finance/CFO | 50 | 21-07-31 |
Cindy Hoots
CTO | Chief Tech/Sci/R&D Officer | 56 | 19-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sherilyn McCoy
BRD | Director/Board Member | 65 | 17-09-30 |
Ahmed Hamdy
PRN | Corporate Officer/Principal | 59 | 13-01-31 |
Philip Broadley
BRD | Director/Board Member | 63 | 17-04-26 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 9.20% | 11 M€ | +0.83% | - | |
| 5.39% | 192 M€ | +11.13% | ||
| 5.17% | 18 M€ | +1.40% | - | |
| 4.89% | 776 M€ | +6.35% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 10,946 | +0.29% | 1,221,642 |
| 24-04-18 | 10,914 | +0.48% | 2,446,630 |
| 24-04-17 | 10,862 | -0.15% | 2,243,525 |
| 24-04-16 | 10,878 | -1.32% | 1,318,970 |
| 24-04-15 | 11,024 | -0.36% | 1,392,030 |
Delayed Quote London S.E., April 19, 2024 at 11:35 am EDT
More quotes
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
Pharmaceuticals
Calendar
2024-04-25
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
135.9
USD
Average target price
161.7
USD
Spread / Average Target
+19.04%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +3.26% | 211B | |
| +24.60% | 672B | |
| +24.08% | 550B | |
| -5.63% | 351B | |
| +15.37% | 317B | |
| +7.38% | 292B | |
| +0.78% | 203B | |
| -9.69% | 144B | |
| -6.63% | 141B | |
| -3.20% | 113B |
- Stock Market
- Equities
- AZN Stock
